BE2017C028I2 - - Google Patents
Info
- Publication number
- BE2017C028I2 BE2017C028I2 BE2017C028C BE2017C028C BE2017C028I2 BE 2017C028 I2 BE2017C028 I2 BE 2017C028I2 BE 2017C028 C BE2017C028 C BE 2017C028C BE 2017C028 C BE2017C028 C BE 2017C028C BE 2017C028 I2 BE2017C028 I2 BE 2017C028I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2017C028I2 true BE2017C028I2 (member.php) | 2025-09-10 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2017C028C BE2017C028I2 (member.php) | 2005-01-26 | 2017-08-03 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (member.php) |
| JP (1) | JP5576591B2 (member.php) |
| KR (1) | KR101468216B1 (member.php) |
| AU (1) | AU2006209547C1 (member.php) |
| BE (1) | BE2017C028I2 (member.php) |
| CA (1) | CA2594713A1 (member.php) |
| CY (2) | CY1119393T1 (member.php) |
| DK (1) | DK1849470T4 (member.php) |
| ES (1) | ES2630002T5 (member.php) |
| FI (1) | FI1849470T4 (member.php) |
| FR (1) | FR17C1028I2 (member.php) |
| HU (2) | HUE033306T2 (member.php) |
| LT (2) | LT1849470T (member.php) |
| LU (1) | LUC00036I2 (member.php) |
| NL (1) | NL300889I2 (member.php) |
| PL (1) | PL1849470T5 (member.php) |
| PT (1) | PT1849470T (member.php) |
| RU (1) | RU2394581C2 (member.php) |
| SI (1) | SI1849470T2 (member.php) |
| TW (1) | TWI362265B (member.php) |
| WO (1) | WO2006080327A1 (member.php) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| LT1849470T (lt) | 2005-01-26 | 2017-07-25 | Taiho Pharmaceutical Co., Ltd. | Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| US8536188B2 (en) * | 2007-04-25 | 2013-09-17 | Cyclacel Limited | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
| CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| DK2273983T3 (en) | 2008-05-09 | 2016-09-19 | Gruenenthal Gmbh | A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin |
| CA2723944A1 (en) * | 2008-05-15 | 2009-11-19 | Jan Balzarini | Anti-cancer combination therapy |
| NZ596667A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Hot-melt extruded controlled release dosage form |
| MX2012000369A (es) | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion. |
| CN103269688A (zh) | 2010-09-02 | 2013-08-28 | 格吕伦塔尔有限公司 | 包含无机盐的抗破碎剂型 |
| AU2011297892B2 (en) | 2010-09-02 | 2014-05-29 | Grunenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| SI2736495T1 (sl) | 2011-07-29 | 2017-12-29 | Gruenenthal Gmbh | Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila |
| BR112014001091A2 (pt) | 2011-07-29 | 2017-02-14 | Gruenenthal Gmbh | comprimido resistente à adulteração que fornece liberação imediata do fármaco |
| SMT201800108T1 (it) | 2011-08-16 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Agente antitumorale e metodo di previsione dell'effetto terapeutico per pazienti con cancro colorettale con kras mutato |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| WO2013137284A1 (ja) | 2012-03-14 | 2013-09-19 | 日清ファルマ株式会社 | 含硫アミノ酸含有組成物 |
| PL2838512T3 (pl) | 2012-04-18 | 2018-12-31 | Grünenthal GmbH | Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| EP2849756A1 (en) * | 2012-05-16 | 2015-03-25 | Novartis AG | Dosage regimen for a pi-3 kinase inhibitor |
| HRP20201691T1 (hr) * | 2013-03-27 | 2020-12-25 | Taiho Pharmaceutical Co., Ltd. | Antitumorni agens koji uključuje irinotekan hidroklorid hidrat |
| UA117581C2 (uk) * | 2013-03-27 | 2018-08-27 | Тайхо Фармасьютікал Ко., Лтд. | Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат |
| AU2014266278B2 (en) * | 2013-05-17 | 2017-07-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of TK1 protein has increased |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| WO2015004245A1 (en) | 2013-07-12 | 2015-01-15 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| HRP20230523T1 (hr) | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| HK1224189A1 (zh) | 2013-11-26 | 2017-08-18 | Grünenthal GmbH | 通过低温研磨制备粉状药物组合物 |
| AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
| AU2015266117A1 (en) | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
| JP6871868B2 (ja) * | 2016-01-08 | 2021-05-19 | 大鵬薬品工業株式会社 | 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| JP6882205B2 (ja) * | 2016-02-05 | 2021-06-02 | 大鵬薬品工業株式会社 | 重度腎機能障害を有する癌患者に対する治療方法 |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| US20260021045A1 (en) * | 2024-07-17 | 2026-01-22 | Jnd Therapeutics, Inc. | Methods and formulations for treatment of liver cancer using trifluridine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744475A (en) * | 1995-03-29 | 1998-04-28 | Taiho Pharmaceutical Co., Ltd. | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| PT884051E (pt) * | 1996-09-24 | 2005-03-31 | Taiho Pharmaceutical Co Ltd | Inibidores de metasteses cancerosas contendo derivados de uracilo |
| LT1849470T (lt) | 2005-01-26 | 2017-07-25 | Taiho Pharmaceutical Co., Ltd. | Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius |
-
2006
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en not_active Expired
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown